Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics gets European patent for Microcrystalline Tyrosine technology

Similar patents have already been granted in the UK and in New Zealand
a mosquito biting the flesh of a human
When coupled with another adjuvant, MCT has shown positive efficacy in a malaria model

Allergy Therapeutics plc (LON:AGY) has strengthened its core intellectual property after the European Patent Office granted it a broad technology patent for its Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process.

The patent covers the novel manufacture and physiochemical characteristics of MTC in combination with one or more antigens, Allergy said.

The company had already been granted similar patents in the UK and in New Zealand for the MCT technology.

“We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines,” said chief executive Manuel Llobet.

“This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines.”

An adjuvant is a substance which enhances the body’s immune response to an antigen. In the case of MCT, it extends the time available for the immune system to process an antigen.

Recent data has shown that MCT has a synergistic effect when coupled with another adjuvant, Virus Like Particles.

This combined adjuvant system demonstrated positive efficacy in a malaria model in a study performed in collaboration with the University of Oxford.

Shares were up 5% in early deals on Wednesday.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies
picture of seeds
July 18 2017
Finncap's revenue forecasts were upgraded by 6% and 7% to £72.2mln and £79.5mln for the full year 2017 and 2018 respectively.
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use